Open AccessConventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
Author(s) -
JooSeok Song,
Do Young Kim
Publication year - 2017
Publication title -
world journal of hepatology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v9.i18.808
Subject(s) - medicine , hepatocellular carcinoma , drug , stage (stratigraphy) , liver cancer , cancer , oncology , gastroenterology , pharmacology , paleontology , biology
Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drug-eluting beads (DEBs) have been imposed as novel drug-delivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE. Despite the theoretical advantages of DEB-TACE, it is still controversial in clinical practice as to whether DEB-TACE is superior to cTACE in regard to overall survival and treatment response. In this review article, we summarize the clinical efficacy and safety of DEB-TACE for patients with intermediate or advanced stage HCC in comparison with cTACE.